Breaking Business News: AbbVie To Acquire Apogee Therapeutics - The Dermatology Digest
AbbVie is set to acquire Apogee Therapeutics and its pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting interleukin (IL)-13 in atopic dermatitis (AD). Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. […]
AbbVie is set to acquire Apogee Therapeutics and its pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting interleukin (IL)-13 in atopic dermatitis (AD). Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. […]
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
